SEARCH

SEARCH BY CITATION

References

  • 1
    Abbas AK, Lichtman AH. Cellular and molecular immunology, 6th edn. Philadelphia, USA: WB Saunders Company, 2005.
  • 2
    Weber RW. Adverse reactions to biological modifiers. Curr Opin Allergy Clin Immunol 2004;4:277283.
  • 3
    Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000;23:483507.
  • 4
    Hoigne R, Schlumberger HP, Vervloet D, Zoppi M. Epidemiology of allergic drug reactions. Monogr Allergy 1993;31:147170.
  • 5
    Coombs RR, Gell GP. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: CoombsRR, ed. Clinical aspects of immunology. Oxford, UK: Oxford Univ Press, 1968:575596.
  • 6
    Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003;139:683693.
  • 7
    Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495497.
  • 8
    Walker C, Herzog C, Rieber P, Riethmuller G, Muller W, Pichler WJ. Anti-CD4 antibody treatment of patients with rheumatoid arthritis: II. Effect of in vivo treatment on in vitro proliferative response of CD4 cells. J Autoimmun 1989;2:643649.
  • 9
    Waugh J, Perry CM. Anakinra: a review of its use in the management of rheumatoid arthritis. BioDrugs 2005;19:189202.
  • 10
    Lee SJ, Kavanaugh A. Adverse reactions to biological agents: focus on autoimmune disease therapies. J Allergy Clin Immunol 2005;116:900905.
  • 11
    Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787793.
  • 12
    Vasquez EM, Fabrega AJ, Pollak R. OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity. Transplant Proc 1995;27:873874.
  • 13
    Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;23:52355246.
  • 14
    Chatenoud L. Immunologic monitoring during OKT3 therapy. Clin Transplant 1993;7(4 Pt 2):422430.
  • 15
    Boven K, Knight J, Bader F, Rossert J, Eckardt KU, Casadevall N. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant 2005;20(Suppl. 3):iii3340.
  • 16
    Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601608.
  • 17
    Lipsky PE, Van Der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:15941602.
  • 18
    Abramowicz D, Crusiaux A, Goldman M. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med 1992;327:736.
  • 19
    Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs 2004;64:17671777.
  • 20
    Arimura K, Arima N, Ohtsubo H, Matsushita K, Kukita T, Ayukawa T et al. Severe autoimmune thrombocytopenic purpura during interferon-alpha therapy for chronic myelogenous leukemia. Acta Haematol 2004;112:217218.
  • 21
    Werth VP, Levinson AI. Etanercept-induced injection site reactions: mechanistic insights from clinical findings and immunohistochemistry. Arch Dermatol 2001;137:953955.
  • 22
    Kassiotis G, Kollias G. TNF and receptors in organ-specific autoimmune disease: multi-layered functioning mirrored in animal models. J Clin Invest 2001;107:15071508.
  • 23
    Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003;125:3239.
  • 24
    Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004;20:539550.
  • 25
    Hershberger RE, Starling RC, Eisen HJ, Bergh CH, Kormos RL, Love RB et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005;352:27052713.
  • 26
    Wellington K, Perry CM. Efalizumab. Am J Clin Dermatol 2005;6:113118; discussion 119–120.
  • 27
    Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:21222127.
  • 28
    Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:83728377.
  • 29
    Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003;22:5661.
  • 30
    Seckin D, Durusoy C, Sahin S. Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr Dermatol 2004;21:577579.
  • 31
    Day R. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet 2002;359:540541.
  • 32
    Solans R, Bosch JA, Esteban I, Vilardell M. Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis. Clin Exp Rheumatol 2004;22:625628.
  • 33
    Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005;24:178181.
  • 34
    Boz C, Ozmenoglu M, Aktoz G, Velioglu S, Alioglu Z. Guillain-Barre syndrome during treatment with interferon alpha for hepatitis B. J Clin Neurosci 2004;11:523525.
  • 35
    Doi F, Kakizaki S, Takagi H, Murakami M, Sohara N, Otsuka T et al. Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int 2005;25:242246.
  • 36
    Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005;204:2742.
  • 37
    Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 2003;206:388390.
  • 38
    Chan JL, Davis-Reed L, Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol 2004;3:315318.
  • 39
    Menon Y, Cucurull E, Reisin E, Espinoza LR. Interferon-alpha-associated sarcoidosis responsive to infliximab therapy. Am J Med Sci 2004;328:173175.
  • 40
    Taylor A, Verhagen J, Akdis CA, Akdis M. T regulatory cells in allergy and health: a question of allergen specificity and balance. Int Arch Allergy Immunol 2004;135:7382.
  • 41
    Danese S, Fiocchi C. Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol 2005;25:103121.
  • 42
    Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807811.
  • 43
    Kasahara A, Hiraide A, Tomita N, Iwahashi H, Imagawa A, Ohguro N et al. Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C. J Gastroenterol 2004;39:11061109.
  • 44
    Bagheri H, Fouladi A, Barange K, Lapeyre-Mestre M, Payen JL, Montastruc JL et al. Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy. Pharmacotherapy 2004;24:15461553.
  • 45
    Chamberlain AJ, Poon E. Cutaneous reactions to interferon and ribavirin. Intern Med J 2004;34:519.
  • 46
    Panwar P, Iznaga-Escobar N, Mishra P, Srivastava V, Sharma RK, Chandra R et al. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody or egf/r3 for targeted tumor imaging and therapy. Cancer Biol Ther 2005;4:814.